Disease Categories Offered

The field of neurology has undergone a profound transformation with the advent of genomic analysis, illuminating the intricate genetic underpinnings of neurological disorders. This groundbreaking technology empowers us to identify the genetic mutations that lie at the heart of neurological conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and various forms of epilepsy. Deciphering these genetic blueprints not only deepens our understanding of disease mechanisms but also paves the way for the development of novel therapeutic strategies.

The GCR Neurology platform harnesses the power of genomic analysis to unravel the genetic predispositions that make certain individuals more susceptible to neurological disorders. This invaluable knowledge empowers healthcare providers to implement preventive measures, recommend lifestyle modifications, and tailor interventions to delay or even prevent disease onset.

Key Features and Benefits of GCR Neurology

  • Unravels the Genetic Tapestry of Neurological Disorders: Identify the genetic mutations associated with a wide spectrum of neurological conditions.
  • Deciphers Disease Mechanisms: Gain a deeper understanding of the underlying biological processes driving neurological disorders
  • Facilitates Precision Medicine: Pave the way for personalized treatment approaches tailored to each patient's unique genetic makeup.
  • Empowers Early Intervention Strategies: Implement preventive measures and lifestyle modifications to delay or mitigate disease onset.

With GCR Neurology, we embark on a transformative journey towards a future where neurological disorders are no longer insurmountable obstacles but manageable conditions, empowering individuals to lead fulfilling and enriching lives.

Therapeutics

Navigating the Therapeutic Landscape

Empower your treatment decisions with a comprehensive guide to FDA-approved targeted therapies based on genomic biomarkers.

Key Points

  • Uncover personalized treatment options tailored to your unique genetic profile.
  • Explore the latest FDA-approved therapies backed by robust clinical evidence.
  • Gain insights into the science behind genomic biomarkers and their impact on treatment response.
  • Navigate the complex therapeutic landscape with confidence and informed decision-making.

Pharmacogenomics

Embrace Personalized Therapeutics: Tailored Treatment for a Healthier You

Our cutting-edge precision medicine platform harnesses the power of genetic information to revolutionize healthcare. By analyzing your unique genetic makeup, we can provide personalized treatment plans that are safer, more effective, and tailored to your individual needs.

Key Benefits

  • Prevent Over-dosing and Under-dosing: Accurately determine the most effective drug dosages based on your genetics, minimizing side effects and maximizing treatment outcomes.
  • Personalized Treatment Plans: Identify the most effective drugs for your specific genetic makeup, ensuring optimal treatment efficacy and reducing adverse reactions.
  • Empowering Patients: Make informed healthcare decisions guided by genetic insights, taking charge of your health for a brighter future.

Prevalence

Neurological disorders are among the leading causes of disability worldwide, affecting an estimated one billion people. This number is projected to increase as the global population ages and the burden of chronic diseases rises.

  • Headaches, the most prevalent neurological disorder, afflict nearly half of the world's population.
  • Epilepsy, characterized by recurrent seizures, affects approximately 50 million people globally.
  • Stroke, a major cause of death and disability, strikes an estimated 17 million individuals annually.
  • Parkinson's disease, disrupting movement and coordination, affects around 10 million people worldwide.
  • Alzheimer's disease, the most common form of dementia, impacts an estimated 55 million people globally.

The impact of neurological disorders extends beyond individuals, affecting families, caregivers, and healthcare systems.

Covered Disease Types and Sub-Types

  • Amyotrophic Lateral Sclerosis Type 1
  • Amyotrophic Lateral Sclerosis Type 10
  • Amyotrophic Lateral Sclerosis Type 11
  • Amyotrophic Lateral Sclerosis Type 12
  • Amyotrophic Lateral Sclerosis Type 15
  • Amyotrophic Lateral Sclerosis Type 16
  • Amyotrophic Lateral Sclerosis Type 18
  • Amyotrophic Lateral Sclerosis Type 19
  • Amyotrophic Lateral Sclerosis Type 2
  • Amyotrophic Lateral Sclerosis Type 20
  • Amyotrophic Lateral Sclerosis Type 21
  • Amyotrophic Lateral Sclerosis Type 23
  • Amyotrophic Lateral Sclerosis Type 4
  • Amyotrophic Lateral Sclerosis Type 5
  • Amyotrophic Lateral Sclerosis Type 6
  • Amyotrophic Lateral Sclerosis Type 8
  • Amyotrophic Lateral Sclerosis Type 9

  • Craniosynostosis Type 2
  • Craniosynostosis Type 4
  • Craniosynostosis Type 5
  • Craniosynostosis Type 6

  • Behavioral Variant Of Frontotemporal Dementia
  • Frontotemporal Dementia
  • Pick Disease
  • Progressive Non-Fluent Aphasia
  • Semantic Dementia

  • Huntingtons Disease-Like 1
  • Huntingtons Disease-Like 2

  • Hyperekplexia Type 1
  • Hyperekplexia Type 2
  • Hyperekplexia Type 3
  • Hyperekplexia Type 4

  • Joubert Syndrome Type 1
  • Joubert Syndrome Type 10
  • Joubert Syndrome Type 13
  • Joubert Syndrome Type 14
  • Joubert Syndrome Type 15
  • Joubert Syndrome Type 16
  • Joubert Syndrome Type 17
  • Joubert Syndrome Type 18
  • Joubert Syndrome Type 2
  • Joubert Syndrome Type 20
  • Joubert Syndrome Type 21
  • Joubert Syndrome Type 22
  • Joubert Syndrome Type 23
  • Joubert Syndrome Type 24
  • Joubert Syndrome Type 25
  • Joubert Syndrome Type 26
  • Joubert Syndrome Type 27
  • Joubert Syndrome Type 28
  • Joubert Syndrome Type 3
  • Joubert Syndrome Type 30
  • Joubert Syndrome Type 31
  • Joubert Syndrome Type 32
  • Joubert Syndrome Type 33
  • Joubert Syndrome Type 35
  • Joubert Syndrome Type 36
  • Joubert Syndrome Type 5
  • Joubert Syndrome Type 6
  • Joubert Syndrome Type 7
  • Joubert Syndrome Type 8
  • Joubert Syndrome Type 9
  • Joubert Syndrome With Hepatic Defect
  • Joubert Syndrome With Jeune Asphyxiating Thoracic Dystrophy
  • Joubert Syndrome With Ocular Defect
  • Joubert Syndrome With Renal Defect

  • Meier-Gorlin Syndrome 1
  • Meier-Gorlin Syndrome 2
  • Meier-Gorlin Syndrome 3
  • Meier-Gorlin Syndrome 4
  • Meier-Gorlin Syndrome 5
  • Meier-Gorlin Syndrome 6
  • Meier-Gorlin Syndrome 7
  • Meier-Gorlin Syndrome 8

  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 10
  • Spinocerebellar Ataxia Type 11
  • Spinocerebellar Ataxia Type 12
  • Spinocerebellar Ataxia Type 13
  • Spinocerebellar Ataxia Type 14
  • Spinocerebellar Ataxia Type 15
  • Spinocerebellar Ataxia Type 16
  • Spinocerebellar Ataxia Type 17
  • Spinocerebellar Ataxia Type 18
  • Spinocerebellar Ataxia Type 19
  • Spinocerebellar Ataxia Type 2
  • Spinocerebellar Ataxia Type 20
  • Spinocerebellar Ataxia Type 21
  • Spinocerebellar Ataxia Type 22
  • Spinocerebellar Ataxia Type 23
  • Spinocerebellar Ataxia Type 24
  • Spinocerebellar Ataxia Type 25
  • Spinocerebellar Ataxia Type 26
  • Spinocerebellar Ataxia Type 27
  • Spinocerebellar Ataxia Type 28
  • Spinocerebellar Ataxia Type 29
  • Spinocerebellar Ataxia Type 31
  • Spinocerebellar Ataxia Type 34
  • Spinocerebellar Ataxia Type 35
  • Spinocerebellar Ataxia Type 36
  • Spinocerebellar Ataxia Type 37
  • Spinocerebellar Ataxia Type 38
  • Spinocerebellar Ataxia Type 40
  • Spinocerebellar Ataxia Type 41
  • Spinocerebellar Ataxia Type 42
  • Spinocerebellar Ataxia Type 43
  • Spinocerebellar Ataxia Type 44
  • Spinocerebellar Ataxia Type 46
  • Spinocerebellar Ataxia Type 47
  • Spinocerebellar Ataxia Type 48
  • Spinocerebellar Ataxia Type 5
  • Spinocerebellar Ataxia Type 6
  • Spinocerebellar Ataxia Type 7
  • Spinocerebellar Ataxia with Axonal Neuropathy Type 1
  • Spinocerebellar Ataxia with Axonal Neuropathy Type 2
  • JSpinocerebellar Ataxia with Axonal Neuropathy Type 3

  • Tay-Sachs Disease AB Variant
  • Tay-Sachs Disease B1 Variant